Drug Database
PR

prednisolone

✓ Approved

Takeda · NR3C1 · Small Molecule

What is prednisolone?

prednisolone is a small molecule developed by Takeda. It is approved for therapeutic indications via oral (po).

Drug Profile

CompanyTakeda
Drug ClassSmall Molecule
Molecular TargetNR3C1
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Takeda

Mechanism of Action

Molecular Targets

prednisolone acts on 1 molecular target:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

prednisolone is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Plasma cell myeloma✓ Approved

Related Research Articles

PubMedInternational journal of dermatology2026-10-16

IgG4-Related Disease Presenting as Inflammatory Midline Pseudotumor of the Face and Neck.

Kwan Rowena Lee Ying RLY, Lee Joyce Siong See JSS, Chua Choon Guan CG, Bundele Manish Mahadeorao MM et al.

A 78-year-old Chinese woman presented with a one-year history of a progressively enlarging purpuric rash over the central face and nasal dorsum, with subsequent development of a firm midline neck mass. Histopathology revealed dense lymphoplasmacytic infiltrate with fibrosis and obliterative phlebitis. Immunohistochemistry showed over 200 IgG4-positive plasma cells per high-power field with an IgG4-IgG ratio exceeding 40%, and serum IgG4 was markedly elevated at 3648.0 mg/L, confirming IgG4-related disease (IgG4-RD) with a head-and-neck limited phenotype. She responded well to prednisolone. This case illustrates a rare cutaneous presentation of IgG4-RD, which should be considered in differential diagnoses of head and neck lesions.

PMID 42885337
Read full article →
PubMedAnimals : an open access journal from MDPI2026-10-16

Candida albicans Urinary Tract Infection with Suspected Fungal Hepatobiliary Disease in an Immunosuppressed Dog: A Case Report.

Norman Amy A, Walton-Clark Michelle M

Fungal urinary tract infections (UTIs) are uncommon in dogs and are typically associated with immunocompromised patients or those with other predisposing factors. Fungal hepatobiliary disease is rarely reported in the veterinary literature. This case report describes a dog on dual immunosuppressive therapy for suspected immune-mediated polyarthritis that developed a hepatopathy suspected to represent bacterial hepatobiliary disease and was subsequently treated with prolonged amoxicillin-clavulanate therapy. Following treatment, the dog developed marked hepatocellular enzyme elevations together with a Candida albicans UTI. Given the patient's progressive hepatocellular injury, clinical signs, history of immunosuppression and antibiotic therapy, concurrent fungal hepatobiliary involvement was suspected. Following initiation of oral fluconazole, the fungal UTI resolved, and there was marked improvement, with subsequent normalisation of ALT and ALP activities. Although the temporal association between antifungal treatment and clinical and biochemical improvement raised suspicion of concurrent fungal hepatobiliary involvement, simultaneous discontinuation of amoxicillin-clavulanate, substantial reduction in prednisolone dose, and continuation of hepatoprotective therapy precluded attribution of the improvement specifically to antifungal treatment. This case highlights the potential for opportunistic fungal disease in immunosuppressed dogs, particularly following prolonged antimicrobial exposure, and illustrates the diagnostic challenges associated with suspected hepatobiliary involvement.

PMID 42883105
Read full article →
PubMedJournal of clinical medicine2026-10-16

Cutaneous Deterioration Following Glucocorticoid Discontinuation in Psoriatic Arthritis: A Real-World Cohort Study.

Gratton Clara C, Ehrenstein Boris B, Günther Florian F, Schminke Louisa L et al.

Background/Objectives: To evaluate the frequency of documented cutaneous deterioration within three months after complete discontinuation of systemic glucocorticoid therapy in psoriatic arthritis (PsA) and to assess a potential association with cumulative glucocorticoid exposure. Methods: This retrospective single-centre cohort study included 100 patients with PsA fulfilling CASPAR criteria who received systemic glucocorticoids at a tertiary rheumatology centre between 2008 and 2024. The primary endpoint was the occurrence of cutaneous deterioration within three months after complete glucocorticoid discontinuation. Associations with cumulative prednisolone-equivalent dose were analysed using logistic regression. Results: Cutaneous deterioration occurred in 10% of patients within three months after glucocorticoid discontinuation. Only a minority of cases were clinically pronounced; no erythrodermic or generalized pustular flares were observed. No statistically significant association between cumulative glucocorticoid exposure and cutaneous deterioration was found (OR 0.90; 95% CI 0.67-1.22). Conclusions: In this real-world PsA cohort, documented cutaneous deterioration following glucocorticoid discontinuation was infrequent and predominantly mild. No statistically significant association between cumulative glucocorticoid exposure and cutaneous deterioration was detected. However, due to the absence of a control group, no conclusions can be drawn regarding a causal relationship between glucocorticoid discontinuation and subsequent skin deterioration.

PMID 42881821
Read full article →
PubMedEuropean journal of endocrinology2026-10-15

Carbonyl Reductase 1 regulates prednisolone clearance and modifies its adverse effect profile.

Pofi Riccardo R, Potter Tom T, Coll Sergi S, Othonos Nantia N et al.

Prednisolone is widely prescribed but associated with marked interindividual variability in adverse effects. While 11β-hydroxysteroid dehydrogenase (11β-HSD) enzymes regulate glucocorticoid activation, the contribution of alternative clearance pathways remains unclear. We aimed to characterize prednisolone metabolism beyond 11β-HSD enzymes, define the roles of carbonyl reductase 1 (CBR-1) and AKR1C1, and assess the clinical relevance of specific metabolites. Post-hoc targeted metabolomic analysis of a randomized, double-blind, placebo-controlled trial combined with mechanistic in vitro overexpression studies. Thirty healthy male volunteers from the TICSI trial (NCT03111810) and HEK293 cells overexpressing CBR-1 or AKR1C1 were studied. Participants received prednisolone (20 mg daily for one week) with placebo or the selective 11β-HSD1 inhibitor AZD4017. In vitro, transfected HEK293 cells were treated with prednisolone or prednisone. Steroid metabolites were quantified by targeted LC-MS/MS, and associations with glucose disposal and osteocalcin were assessed. 20β-reduced metabolites were major contributors to prednisolone clearance. In vitro, CBR-1 preferentially reduced prednisone, with 20β-dihydro-prednisone accounting for up to 78% of its clearance, whereas AKR1C1 had minimal impact. In vivo, 11β-HSD1 inhibition reduced prednisolone exposure without a compensatory rise in prednisone, with a relative increase in CBR-1-mediated 20β-reduction. Higher circulating 20β-dihydro-prednisone at 4 hours independently predicted improved glucose disposal and higher osteocalcin levels. CBR-1 is a key determinant of prednisolone and prednisone clearance in humans and is associated with clinically relevant metabolic and skeletal outcomes. Circulating 20β-dihydro-prednisone may serve as an informative biomarker of glucocorticoid exposure and adverse effect risk, supporting metabolite-guided approaches to glucocorticoid therapy.

PMID 42876382
Read full article →
PubMedAmerican journal of hematology2026-10-15

Combination Therapy of Vinblastine, Prednisolone, Methotrexate, and 6-Mercaptopurine as a Front-Line Therapy for Adult Patients With Langerhans Cell Histiocytosis.

Sato Aki A, Yusa Nozomi N, Tanaka Yukihisa Y, Ogawa Miho M et al.

PMID 42875893
Read full article →
PubMedOcular immunology and inflammation2026-10-15

Posterior Scleritis Following Uneventful Small-Incision Cataract Surgery.

Dhiman Richa R, Bajpai Vidhi V

Posterior scleritis following routine, uncomplicated cataract surgery in a patient without underlying systemic disease is an exceedingly rare and potentially sight-threatening clinical entity. A 55-year-old female with no systemic medical history presented three weeks after uneventful small-incision cataract surgery (SICS) in the right eye with sudden vision loss, redness, and severe ocular pain exacerbated by eye movements. Her best-corrected visual acuity (BCVA) had deteriorated from 6/9 to finger counting close to her face. Dilated fundus examination revealed multiple dull yellow subretinal lesions across the posterior pole. Optical coherence tomography (OCT) showed hyperreflective vitreous cells, subretinal fluid (SRF), and choroidal undulations. B-scan ultrasonography confirmed diffuse posterior scleritis, demonstrating localized sclerochoroidal thickening and fluid accumulation in the sub-Tenon's space. Comprehensive laboratory testing and imaging ruled out infectious and autoimmune etiologies. The patient was treated with high-dose intravenous pulse methylprednisolone (1 g/day for three days) followed by an oral prednisolone taper, which led to immediate pain relief and anatomical resolution. At six months, the scleritis had completely resolved with a BCVA improvement to 6/12, limited by persistent localized disruption of the foveal ellipsoid zone on OCT. The patient remained recurrence-free at six months. Diffuse posterior scleritis can occur as a postoperative inflammatory phenomenon following uneventful cataract surgery. Clinicians must maintain a high index of suspicion, utilize B-scan ultrasonography for diagnosis, and initiate prompt systemic corticosteroid therapy to optimize anatomical and visual outcomes.

PMID 42878057
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about prednisolone